Reduction of primary tumor growth and metastasis in models of triple-negative breast cancer following tilorone administration via type I interferon signaling.

Breast Cancer Res · 2026 · PMC13321603 · PMID 42098864

Europe PMC DOI

hedged sentence

0.0734

closest p · 1.5× alpha

0.0734

boldest claim

The sentences

showed a trendp = 0.0734so close (0.05 < p ≤ 0.1)

CD8 + T cells showed a trend towards increased numbers in the primary tumor with tilorone treatment relative to the vehicle cohort ( p = 0.0734, Supplemental Fig. 5 D), as did the number of CD69 + /CD8 + T cells compared to the doxorubicin group ( p = 0.0201) and the combination treatment group ( p = 0.08, Supplemental Fig. 5 E, F).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.